<DOC>
	<DOCNO>NCT01636037</DOCNO>
	<brief_summary>Dopamine , chemical brain , link schizophrenia number year . More recently , evidence certain area affect schizophrenia ( e.g . motivation , cognition ) may reflect little dopamine , whereas symptom like hallucination delusion link much dopamine . This study design evaluate safety , tolerability , efficacy give L-dopa ( Sinemet ) see improve symptom related little dopamine . L-dopa approve medical condition ( e.g . Parkinson 's disease ) work increase level dopamine . The investigator link study neuroimaging ( fMRI ) allow u link change investigator might find clinical symptom change brain . This information prove useful well understanding mechanisms account symptom , well possible new treatment . At present , treatment symptoms seem important functional measure outcome ( i.e . deficit symptom , include amotivation ; cognitive symptom ) schizophrenia prove particularly effective . It hop L-dopa may provide treatment effective ; go forward , information would also useful drug development future line investigation . 1 . L-dopa prove effective improving deficit ( also call 'primary negative ' e.g . amotivation ) cognitive symptom schizophrenia . 2 . It well tolerate increase risk psychotic symptom administer conjunction regular antipsychotic medication .</brief_summary>
	<brief_title>Antipsychotic Augmentation With L-Dopa</brief_title>
	<detailed_description>Pharmacological ( non-pharmacological ) strategy may significantly improve negative cognitive symptom schizophrenia represent critical unmet therapeutic need . There wide acceptance notion negative cognitive symptom best understood feature hypo- rather hyperdopaminergic activity . The primary negative cognitive symptom appear central schizophrenia predate neurodevelopmental change subsequently give rise hyperdopaminergic state underlie positive symptom . In use L-Dopa specifically , avoid abuse potential agent psychostimulants , perturbation pharmacological action function dose , observed dopamine agonist . Further , recent neuroimaging study provide vivo evidence keep underlying rationale . First , image study demonstrate L-dopa induces shift activity cortical subcortical structure link reward , affect cognition . Along similar line , L-dopa-induced change associate improvement motivation , cognitive task , affect .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>SCIDconfirmed ( Structured Clinical Interview DSMIV Axis I Disorders ) diagnosis schizophrenia age 1855 history substance abuse dependence within 3 month ; ( ii ) positive urine drug screen history evidence disorder might adversely influence cognitive measure ( e.g . mental retardation ) presence serious neurological general medical condition ( e.g. , Parkinson 's disease , cardiac arrhythmia , epilepsy ) clinical laboratory evidence uncompensated cardiovascular , endocrine , hematologic , hepatic , pulmonary ( include bronchial asthma ) , renal disease , narrowangle glaucoma , malignant melanoma pregnancy/nursing woman childbearing age regular contraceptive therapy ( effect Ldopa unknown )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>negative symptom</keyword>
	<keyword>deficit syndrome</keyword>
	<keyword>SANS</keyword>
	<keyword>Sinemet</keyword>
	<keyword>L-dopa</keyword>
	<keyword>levodopa</keyword>
	<keyword>carbidopa</keyword>
	<keyword>augmentation</keyword>
	<keyword>antipsychotic</keyword>
</DOC>